Misha Fini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Misha Fini has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andy Jinseok Lee
Lineberger Comprehensive Cancer Center, UNC Chapel Hill School of Medicine, Chapel Hill, NC, USA, 27514
3 shared publications - Benjamin G. Vincent
Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3 shared publications - Dhuvarakesh Karthikeyan
Personalized Immunotherapy Research Lab, UNC Chapel Hill
3 shared publications - Alexander Rubinsteyn
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 shared publications - Alex M. Jaeger
H. Lee Moffitt Cancer Center & Research Institute
1 shared publication - Emily Paul
Department of Molecular Oncology, Moffitt Cancer Center, Tampa, FL, USA, 33612
1 shared publication
Latest Publications
- Open Access
Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy
Immune checkpoint inhibition (ICI) is clinically active against multiple cancers, including urothelial cancer at the non-muscle invasive, muscle-invasive, and metastatic stages. Despite this, large numbers of patients experience disease progression and relapse after treatment with ICI-containing regimens. Tumor antigen-specific T cells are critical to ICI response, however few studies have evaluated the breadth and magnitude of tumor antigen-specific T cell responses with ICI therapy. In this study, we mapped the tumor antigen immunodominance hierarchy in the BBN963 model of murine basal-like bladder cancer for endogenous tumor neoantigens expressed physiologically. We used a high-throughput matrixed ELISpot assay to detect CD8 + T cell responses to predicted BBN963 tumor antigens derived from multiple mutational genomic sources. We found CD8+ T cell responses were directed against a subset of tumor antigens forming a stable and reproducible immunodominance hierarchy across individual mice. Treatment with anti-PD-1 or anti-CTLA-4 did not substantially reshape this hierarchy or broadly shift dominant responses to previously defined subdominant epitopes. Predicted peptide MHC binding stability and affinity was associated with antigen immunogenicity. Cancer-testis antigens, endogenous retroviral antigens, and SNV-derived tumor antigens that were immunogenic were found across tumor subclones. By diversifying the immunogenic antigen repertoire beyond SNVs, we achieved nearly 100% tumor subclone coverage, suggesting that broader antigen selection could help immunotherapy target more tumor subclones. In conclusion, this study supports the stability of the immunodominance hierarchy under ICI therapy and a role for broadening antigen discovery to multiple expressional sources in immunotherapy design.
Open AccessImmunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy
Immune checkpoint inhibition (ICI) is clinically active against multiple cancers, including urothelial cancer at the non-muscle invasive, muscle-invasive, and metastatic stages. Despite this, large numbers of patients experience disease progression and relapse after treatment with ICI-containing regimens. Tumor antigen-specific T cells are critical to ICI response, however few studies have evaluated the breadth and magnitude of tumor antigen-specific T cell responses with ICI therapy. In this study, we mapped the tumor antigen immunodominance hierarchy in the BBN963 model of murine basal-like bladder cancer for endogenous tumor neoantigens expressed physiologically. We used a high-throughput matrixed ELISpot assay to detect CD8 + T cell responses to predicted BBN963 tumor antigens derived from multiple mutational genomic sources. We found CD8+ T cell responses were directed against a subset of tumor antigens forming a stable and reproducible immunodominance hierarchy across individual mice. Treatment with anti-PD-1 or anti-CTLA-4 did not substantially reshape this hierarchy or broadly shift dominant responses to previously defined subdominant epitopes. Predicted peptide MHC binding stability and affinity was associated with antigen immunogenicity. Cancer-testis antigens, endogenous retroviral antigens, and SNV-derived tumor antigens that were immunogenic were found across tumor subclones. By diversifying the immunogenic antigen repertoire beyond SNVs, we achieved nearly 100% tumor subclone coverage, suggesting that broader antigen selection could help immunotherapy target more tumor subclones. In conclusion, this study supports the stability of the immunodominance hierarchy under ICI therapy and a role for broadening antigen discovery to multiple expressional sources in immunotherapy design.
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
ACE configurator for ELISpot: optimizing combinatorial design of pooled ELISpot assays with an epitope similarity model
The enzyme-linked immunosorbent spot (ELISpot) assay is a powerful in vitro immunoassay that enables cost-effective quantification of antigen-specific T-cell reactivity. It is used widely in the context of cancer and infectious diseases to validate the immunogenicity of predicted epitopes. While technological advances have kept pace with the demand for increased throughput, efforts to increase scale are bottlenecked by current assay design and deconvolution methods, which have remained largely unchanged. Current methods for designing pooled ELISpot experiments offer limited flexibility of assay parameters, lack support for high-throughput scenarios and do not consider peptide identity during pool assignment. We introduce the ACE Configurator for ELISpot (ACE) to address these gaps. ACE generates optimized peptide-pool assignments from highly customizable user inputs and handles the deconvolution of positive peptides using assay readouts. In this study, we present a novel sequence-aware pooling strategy, powered by a fine-tuned ESM-2 model that groups immunologically similar peptides, reducing the number of false positives and subsequent confirmatory assays compared to existing combinatorial approaches. To validate ACE’s performance on real-world datasets, we conducted a comprehensive benchmark study, contextualizing design choices with their impact on prediction quality. Our results demonstrate ACE’s capacity to further increase precision of identified immunogenic peptides, directly optimizing experimental efficiency. ACE is freely available as an executable with a graphical user interface and command-line interfaces at https://github.com/pirl-unc/ace.
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Open AccessACE configurator for ELISpot: optimizing combinatorial design of pooled ELISpot assays with an epitope similarity model
The enzyme-linked immunosorbent spot (ELISpot) assay is a powerful in vitro immunoassay that enables cost-effective quantification of antigen-specific T-cell reactivity. It is used widely in the context of cancer and infectious diseases to validate the immunogenicity of predicted epitopes. While technological advances have kept pace with the demand for increased throughput, efforts to increase scale are bottlenecked by current assay design and deconvolution methods, which have remained largely unchanged. Current methods for designing pooled ELISpot experiments offer limited flexibility of assay parameters, lack support for high-throughput scenarios and do not consider peptide identity during pool assignment. We introduce the ACE Configurator for ELISpot (ACE) to address these gaps. ACE generates optimized peptide-pool assignments from highly customizable user inputs and handles the deconvolution of positive peptides using assay readouts. In this study, we present a novel sequence-aware pooling strategy, powered by a fine-tuned ESM-2 model that groups immunologically similar peptides, reducing the number of false positives and subsequent confirmatory assays compared to existing combinatorial approaches. To validate ACE’s performance on real-world datasets, we conducted a comprehensive benchmark study, contextualizing design choices with their impact on prediction quality. Our results demonstrate ACE’s capacity to further increase precision of identified immunogenic peptides, directly optimizing experimental efficiency. ACE is freely available as an executable with a graphical user interface and command-line interfaces at https://github.com/pirl-unc/ace.
- Open Access
ACE Configurator for ELISpot (ACE): Optimizing Combinatorial Design of Pooled ELISpot Assays with an Epitope Similarity Model
The ELISpot assay is a powerful in vitro immunoassay that enables cost-effective quantification of antigen-specific T-cell reactivity. It is widely used in the context of cancer and infectious diseases to validate the immunogenicity of epitopes. While technological advances in hardware and software have kept pace with the need for increased throughput, assay design and deconvolution methodology have largely remained stagnant. Current methods for designing multiplexed ELISpot assays are restricted to preset configurations, lack support for high-throughput scenarios, and ignore peptide identity during pool assignment. We introduce the ACE Configurator for ELISpot (ACE) to address these gaps. ACE generates optimized peptide-pool assignments from highly customizable user inputs and handles positive peptide deconvolution using assay readouts. We present a novel sequence-aware pooling strategy, powered by a fine-tuned ESM-2 deep sequence model to identify immunologically similar peptides, reducing the number of false positives and subsequent confirmatory assays. To validate the performance of ACE using real-world datasets, we conducted a comprehensive benchmark study against various design heuristics, deconvolution methods, and experimental conditions, contextualizing design parameter choices with their impact on precision and number of total pools. Our results demonstrate ACE’s capacity to further increase precision of identified immunogenic peptides, maximizing experimental efficiency at the bench-side. ACE is freely available as an executable with a graphical user interface and command-line interfaces at https://github.com/pirl-unc/ace .
Open AccessACE Configurator for ELISpot (ACE): Optimizing Combinatorial Design of Pooled ELISpot Assays with an Epitope Similarity Model
The ELISpot assay is a powerful in vitro immunoassay that enables cost-effective quantification of antigen-specific T-cell reactivity. It is widely used in the context of cancer and infectious diseases to validate the immunogenicity of epitopes. While technological advances in hardware and software have kept pace with the need for increased throughput, assay design and deconvolution methodology have largely remained stagnant. Current methods for designing multiplexed ELISpot assays are restricted to preset configurations, lack support for high-throughput scenarios, and ignore peptide identity during pool assignment. We introduce the ACE Configurator for ELISpot (ACE) to address these gaps. ACE generates optimized peptide-pool assignments from highly customizable user inputs and handles positive peptide deconvolution using assay readouts. We present a novel sequence-aware pooling strategy, powered by a fine-tuned ESM-2 deep sequence model to identify immunologically similar peptides, reducing the number of false positives and subsequent confirmatory assays. To validate the performance of ACE using real-world datasets, we conducted a comprehensive benchmark study against various design heuristics, deconvolution methods, and experimental conditions, contextualizing design parameter choices with their impact on precision and number of total pools. Our results demonstrate ACE’s capacity to further increase precision of identified immunogenic peptides, maximizing experimental efficiency at the bench-side. ACE is freely available as an executable with a graphical user interface and command-line interfaces at https://github.com/pirl-unc/ace .